Kirton said it planned to continue growing the business thanks to the investment through internal growth and acquisitions, and hoped to establish a greater presence overseas.
The company, which was launched 30 years ago by exiting chairman Martin Battye, expanded its business in 2010 by purchasing healthcare market seatmaker AJ Way.
NVM investment directors David Rolfe and James Arrowsmith completed the deal for NVM, with Rolfe set to join the board.
He said, “Design, innovation and strong relationships are at the heart of Kirton’s business.
“They are well-respected in the healthcare industry and their products continually evolve — allowing them to stay ahead of the market.
“We have been very impressed with the management team and look forward to working with them to take advantage of the growing demand for their product both at home in the UK and abroad.”
Earlier this week NVM backed applied environmental biotechnology specialist Cleveland Biotech by providing £3m towards its £4.4m MBO.
The company develops fermented bacteria for use in a range of biological products which naturally degrade a range of organic pollutants including grease, fat, oil, diesel, uric acid and limescale.
It recently doubled its European exports after securing a series of large sales orders from Lithuania.
Copyright © 2013 AltAssets